Evaluation of the Effect of Two Doses of AMR101 (Ethyl Icosapentate) on Fasting Serum Triglyceride Levels in Patients With Persistent High Triglyceride Levels (greater than or equal to 200 mg/dL and less than 500 mg/dL) Despite Statin Therapy.

Trial Profile

Evaluation of the Effect of Two Doses of AMR101 (Ethyl Icosapentate) on Fasting Serum Triglyceride Levels in Patients With Persistent High Triglyceride Levels (greater than or equal to 200 mg/dL and less than 500 mg/dL) Despite Statin Therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Ethyl eicosapentaenoic acid (Primary)
  • Indications Dyslipidaemias; Hypertriglyceridaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms ANCHOR
  • Sponsors Amarin Corporation
  • Most Recent Events

    • 15 Nov 2017 Results presented at the 90th Annual Scientific Sessions of the American Heart Association
    • 13 Nov 2017 Data from this trial presented at the American Heart Association (AHA) 2017 Scientific Sessions, as reported in an Amarin media release
    • 13 Nov 2017 Results published in an Amarin Corporation Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top